Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Public ClinicalTrials.gov record NCT01718353. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Study identification
- NCT ID
- NCT01718353
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Interventions
- CABAZITAXEL (XRP6258) Drug
- DOCETAXEL (XRP6976) Drug
- Prednisone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2013
- Primary completion
- Jul 31, 2015
- Completion
- Jul 31, 2015
- Last update posted
- Nov 19, 2017
2013 – 2015
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840003 | Birmingham | Alabama | 35294-3300 | — |
| Investigational Site Number 840102 | Washington D.C. | District of Columbia | 20016-2695 | — |
| Investigational Site Number 840005 | Indianapolis | Indiana | 46202 | — |
| Investigational Site Number 840025 | Metairie | Louisiana | 70006 | — |
| Investigational Site Number 840002 | Baltimore | Maryland | 21230 | — |
| Investigational Site Number 840007 | Bethesda | Maryland | 20817 | — |
| Investigational Site Number 840017 | Rockville | Maryland | 20850 | — |
| Investigational Site Number 840010 | Cherry Hill | New Jersey | 08003 | — |
| Investigational Site Number 840015 | East Orange | New Jersey | 07018 | — |
| Investigational Site Number 840001 | New York | New York | 10021 | — |
| Investigational Site Number 840013 | New York | New York | 10029-6574 | — |
| Investigational Site Number 840009 | Charleston | South Carolina | 29414 | — |
| Investigational Site Number 840012 | Seattle | Washington | 98109 | — |
| Investigational Site Number 840004 | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01718353, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2017 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01718353 live on ClinicalTrials.gov.